Literature DB >> 23482887

Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells.

Chun-Hui Wei1, Li-Xiu Wei, Ming-Yu Lai, Jia-Zhuang Chen, Xi-Jing Mo.   

Abstract

AIM: To investigate the effect of high mobility group A2 (HMGA2) gene silencing on gastric cancer MKN-45 cells in vitro.
METHODS: HMGA2 short hairpin RNA (shRNA) expression plasmids were constructed, including a pair of random scrambled sequences. Human gastric cancer cell line MKN-45 cells were divided into three groups: blank control group (non-transfected cells), transfected group (cells transfected with HMGA2 shRNA recombinant plasmid) and scrambled sequence group (transfected with random scrambled plasmid). Cells were transfected with HMGA2 shRNA recombinant plasmids and scrambled plasmid in vitro, and the cells transfection efficiency was assayed by fluorescence microscopy. The HMGA2 messenger RNA (mRNA) expression was detected by reverse transcription polymerase chain reaction, gastric cancer cells apoptosis was detected by flow cytometry, cell proliferation was detected by methyl thiazol tetrazolium, and the protein expression of phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), P27, caspase-9 and B-cell leukemia/lymphoma-2 (Bcl-2) were analyzed by Western blotting.
RESULTS: Compared with the blank control group and the scrambled sequence group, the levels of HMGA2 mRNA and protein expression in the transfected group were significantly reduced (P < 0.05). The relative HMGA2 mRNA expression levels of the blank control group, transfected group and scrambled sequence group were 0.674 ± 0.129, 0.374 ± 0.048 and 0.689 ± 0.124, respectively. The relative HMGA2 protein expression levels of the blank control group, transfected group and scrambled sequence group were 0.554 ± 0.082, 0.113 ± 0.032 and 0.484 ± 0.123, respectively. Moreover, transfection with the scrambled sequence had no effect on the expression of HMGA2. After being transfected with shRNA for 24, 48 and 72 h, the cell apoptotic rates of the transfected group were 21.65% ± 0.28%, 39.98% ± 1.82% and 24.51% ± 0.93%, respectively, which significantly higher than those of blank control group (4.72% ± 1.34%, 5.83% ± 0.13% and 5.22% ± 1.07%) and scrambled sequence group (4.28% ± 1.33%, 7.87% ± 1.43% and 6.71% ± 0.92%). After 24, 48 and 72 h, the cell proliferation inhibition rates in the transfected group were 31.57% ± 1.17%, 39.45% ± 2.07% and 37.56% ± 2.32%, respectively; the most obvious cell proliferation inhibition appeared at 48 h after transfection. Compared with the blank control group and scrambled sequence group, after transfection of shRNA for 72 h, the protein expression levels of PI3K (0.042 ± 0.005 vs 0.069 ± 0.003, 0.067 ± 0.05), Akt (0.248 ± 0.004 vs 0.489 ± 0.006, 0.496 ± 0.104) and Bcl-2 (0.295 ± 0.084 vs 0.592 ± 0.072, 0.594 ± 0.109) were significantly reduced. The protein expression levels of P27 (0.151 ± 0.010 vs 0.068 ± 0.014, 0.060 ± 0.013) and caspase-9 (0.136 ± 0.042 vs 0.075 ± 0.010, 0.073 ± 0.072) were significantly upregulated.
CONCLUSION: HMGA2 shRNA gene silencing induces apoptosis and suppresses proliferation of MKN-45 cells.

Entities:  

Keywords:  Apoptosis; Gastric cancer cells; High mobility group A2; Proliferation; RNA interference

Mesh:

Substances:

Year:  2013        PMID: 23482887      PMCID: PMC3587480          DOI: 10.3748/wjg.v19.i8.1239

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

1.  Opposing effects of Bad phosphorylation at two distinct sites by Akt1 and JNK1/2 on ischemic brain injury.

Authors:  Xiao-Tian Wang; Dong-Sheng Pei; Jing Xu; Qiu-Hua Guan; Ya-Feng Sun; Xiao-Mei Liu; Guang-Yi Zhang
Journal:  Cell Signal       Date:  2007-04-27       Impact factor: 4.315

2.  Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.

Authors:  Jacqueline C Shultz; Rachel W Goehe; D Shanaka Wijesinghe; Charuta Murudkar; Amy J Hawkins; Jerry W Shay; John D Minna; Charles E Chalfant
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.

Authors:  Courtney Greider; Anuja Chattopadhyay; Christina Parkhurst; Elizabeth Yang
Journal:  Oncogene       Date:  2002-11-07       Impact factor: 9.867

5.  A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation.

Authors:  Masashi Narita; Masako Narita; Valery Krizhanovsky; Sabrina Nuñez; Agustin Chicas; Stephen A Hearn; Michael P Myers; Scott W Lowe
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

6.  HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer.

Authors:  Gerhild Fabjani; Dan Tong; Andrea Wolf; Sebastian Roka; Sepp Leodolter; Paul Hoecker; Michael Bernhard Fischer; Raimund Jakesz; Robert Zeillinger
Journal:  Oncol Rep       Date:  2005-09       Impact factor: 3.906

Review 7.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

8.  Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 and modulates its DNA binding affinity.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2007-10-26       Impact factor: 4.466

9.  Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.

Authors:  Kazuo Motoyama; Hiroshi Inoue; Yoshito Nakamura; Hiroyuki Uetake; Kenichi Sugihara; Masaki Mori
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

10.  HMGA2 participates in transformation in human lung cancer.

Authors:  Francescopaolo Di Cello; Joelle Hillion; Alexandra Hristov; Lisa J Wood; Mita Mukherjee; Andrew Schuldenfrei; Jeanne Kowalski; Raka Bhattacharya; Raheela Ashfaq; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

View more
  5 in total

1.  The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity.

Authors:  Harpreet Kaur; Marianne Hütt-Cabezas; Melanie F Weingart; Jingying Xu; Yasumichi Kuwahara; Anat Erdreich-Epstein; Bernard E Weissman; Charles G Eberhart; Eric H Raabe
Journal:  J Neuropathol Exp Neurol       Date:  2015-02       Impact factor: 3.685

2.  Identifying key stage-specific genes and transcription factors for gastric cancer based on RNA-sequencing data.

Authors:  Yan Wang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 3.  High Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia.

Authors:  Uchenna Unachukwu; Kiran Chada; Jeanine D'Armiento
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

Review 4.  HMGA2 as a Critical Regulator in Cancer Development.

Authors:  Behzad Mansoori; Ali Mohammadi; Henrik J Ditzel; Pascal H G Duijf; Vahid Khaze; Morten F Gjerstorff; Behzad Baradaran
Journal:  Genes (Basel)       Date:  2021-02-13       Impact factor: 4.096

5.  Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis.

Authors:  Francesca Galdiero; Anna Maria Bello; Anna Spina; Anna Capiluongo; Sophie Liuu; Margot De Marco; Alessandra Rosati; Mario Capunzo; Maria Napolitano; Emilia Vuttariello; Mario Monaco; Daniela Califano; Maria Caterina Turco; Gennaro Chiappetta; Joëlle Vinh; Giovanni Chiappetta
Journal:  Oncotarget       Date:  2018-01-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.